Literature DB >> 20450900

Pre-analytical in-vitro stability of [-2]proPSA in blood and serum.

Axel Semjonow1, Thomas Köpke, Elke Eltze, Beate Pepping-Schefers, Hilla Bürgel, Claude Darte.   

Abstract

OBJECTIVES: [-2]proPSA may discriminate prostate cancer from benign biopsy results. We characterized the pre-analytical stability of [-2]proPSA. DESIGN AND METHODS: 22 volunteers, total PSA of 4.5-19.3microg/L, had blood drawn simultaneously. Baseline measurements were performed and samples were stored under various conditions prior to measurements. Freeze-thaw cycles were performed. [-2]proPSA was measured with the p2PSA automated research use only immunoassay on the Access analyzer.
RESULTS: Mean [-2]proPSA increases with clotting time, exceeding 10% change in recovery after 3h. In serum, [-2]proPSA values decline over time under investigated storage conditions. Serum samples kept frozen show less than 10% variation in recoveries over the course of 2 freeze-thaw cycles.
CONCLUSIONS: For proper measurement of [-2]proPSA, blood samples should be centrifuged within 3h of blood draw. Serum may be stored at RT or refrigerated (+4 degrees C) for a maximum of 48h and should be frozen if stored for a longer period. Two freeze-thaw cycles have no effect on [-2]proPSA stability. Copyright 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450900     DOI: 10.1016/j.clinbiochem.2010.04.062

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  30 in total

1.  A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.

Authors:  Antonino Sottile; Cinzia Ortega; Alfredo Berruti; Monica Mangioni; Sara Saponaro; Alessandra Polo; Veronica Prati; Giovanni Muto; Massimo Aglietta; Filippo Montemurro
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

2.  Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience.

Authors:  Safana S Al Saidi; Nafila B Al Riyami; Mohammed S Al Marhoon; Mohammed S Al Saraf; Salim S Al Busaidi; Riad Bayoumi; Waad-Allah S Mula-Abed
Journal:  Oman Med J       Date:  2017-07

Review 3.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

4.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

Review 5.  Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.

Authors:  Kazuto Ito; Yuji Fujizuka; Kiyohide Ishikura; Bernard Cook
Journal:  Int J Clin Oncol       Date:  2014-08-20       Impact factor: 3.402

6.  Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.

Authors:  Kazuto Ito; Mai Miyakubo; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

7.  Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Authors:  Sigrid V Carlsson; Mari T Peltola; Daniel Sjoberg; Fritz H Schröder; Jonas Hugosson; Kim Pettersson; Peter T Scardino; Andrew J Vickers; Hans Lilja; Monique J Roobol
Journal:  BJU Int       Date:  2013-02-28       Impact factor: 5.588

8.  Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions.

Authors:  Tsukasa Igawa; Kosuke Takehara; Toru Onita; Kazuto Ito; Hideki Sakai
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

9.  Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Authors:  Peter K F Chiu; Monique J Roobol; Jeremy Y Teoh; Wai-Man Lee; Siu-Ying Yip; See-Ming Hou; Chris H Bangma; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-27       Impact factor: 2.370

10.  The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.

Authors:  C F Ng; Peter K F Chiu; N Y Lam; H C Lam; Kim W M Lee; Simon S M Hou
Journal:  Int Urol Nephrol       Date:  2013-10-18       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.